| Participants
We recruited 20 apparently healthy subjects (9 men and 11 women) from laboratory staff in our hospital using a detailed questionnaire and physical examination. ). All volunteer subjects gave informed consent to participate in the study, according to the ethical standards of the China Medical University. Subjects self-reported as healthy, none of the subjects were taking any prescription medication (oral contraceptives excluded) or had any illness during the study, and none of the subjects had thyroid diseases or family history of thyroid diseases.
Women were not pregnant or lactating, and had regular menstrual cycles. The following exclusion criteria were used: major medical illness, smoking, and heavy alcohol use. The subjects' weights were stable during the previous 2 months. The volunteer subjects did not exhibit any acute or chronic disease during our study, and they maintained their usual lifestyle.
| Specimen collection
Blood samples were collected once per week for 5 weeks. All blood samples were collected at the same time of the day (between 7:20 and 8:10 am). The subjects were fasted overnight and seated for 20 minutes. Blood was collected using a standardized method to minimize sources of pre-analytical variation. We used 5-mL BD Vacutainer vacuum collection tubes containing polymer gel for serum collection (Becton Dickinson Biosciences, New York, USA).
Whole blood was allowed to clot for 15 minutes, the serum was separated (3000× g, 10 minutes), and the samples were stored at −80°C. All samples were collected and processed before performing batch analyses.
| Analysis of tumor markers
Samples were thawed for 30 minutes at room temperature, mixed using a vortex-shaking apparatus, and analyzed in duplicate in the same batch in random order. Quality control assessment was performed with satisfactory results before the analyses. One analyst performed all tests using the same reagents (same lot numbers) to minimize analytical variations. The NSE and CA724 levels were measured using a Roche E170 immunology analyzer (Roche Inc., Mannheim, Germany). The reagents (Cancer Antigen 724, 00169337; Neuron-specific enolase, 00170027) and calibration standards (CA724, 00173758; NSE, 00175154) were from Roche. The controls were from Bio-Rad Tumor Marker Plus Control kit (54560).
| Statistical analysis
The Cochran maximum variance test and Dixon test were conducted to identify outliers. The Kolmogorov-Smirnov test was used to ensure normality for all data. The Shapiro-Wilk test was used to ensure data normality for each subject. Biological variation was analyzed using nested analysis of variance and Microsoft Excel. Intra-individual biological variation (CV I ) and inter-individual biological variation (CV G )
were calculated according to the method of Fraser and Harris. 8 The confidence interval (95%CI) for the biological variation of these tumor makers was calculated according to the method of Burdick et al 13 Analytical variation (SD 2 A ) was calculated as the difference between duplicate results for each specimen. Intra-individual biological variation was calculated as the total intra-individual variation minus onehalf of the analytical variation. Inter-individual biological variation was calculated as the total variation minus the analytical variation and the intra-individual variation. Overall means were used to convert the components of biological variation into relevant CV. The index of individuality (II) was calculated using the following equation:
]∕CV G . The reference change value (RCV) was calculated using the following formula:
, where the Z score was 1.96. An RCV with 95% probability was regarded as significant. The number of tests that needed to determine the homeostatic set point for the individual was calculated using the
, where n was the number of specimens obtained, and D was the percentage closeness to the homeostatic set point.
| RESULT

| Subjects and calculations
No visible hemolysis was observed before determining NSE. Most of the results are consistent with normal distributions for the individuals (90% for NSE and 70% for CA724). The Cochran maximum variance test was used to identify outliers and detect precision for repeated measures results. We identified two outliers for NSE and one outlier for CA724. These outliers were removed from the analyses, but other data for the subjects were retained. The Cochran maximum variance test also was used to identify the outliers of the mean values for individuals, and to determine whether the discrete value of the test results for an individual was greater than the discrepancy of the entire population. The results indicated that NSE had one outlier, whereas CA724 had two outliers. We removed all data for these individuals from the analyses. Therefore, a total of 188 data points were used for the statistical analysis of serum NSE, and a total of 178 data points were used for the statistical analysis of serum CA724.
Serum CA724 levels of subject number 2 were high for all data collected during the study. We followed up this subject for 3 years with yearly physical examinations, but did not find any medical condition to explain the anomaly. Therefore, the results for this subject were removed from the analysis.
| Biological variations, indices of individuality, and reference change values for NSE and CA724
The overall means, analytical and biological variations, and II values for NSE and CA724 are presented in Table 1 . The analytical variation was much smaller than the intra-individual biological variation. The II for CA724 was low (<0.6), whereas the II of NSE was larger (0.85). The
RCVs for NSE and CA724 are presented in Table 2 . The results obtained in our study were compared with those of two previous studies (Table 3 ). This comparison revealed that CV I of CA724 was much larger in our study than in previous studies.
| DISCUSSION
Lung and stomach cancer are the most common cancers in China.
14 NSE and CA724 tumor markers provide important information for the treatment and follow-up of these patients. However, little was known about the biological variations of these markers. The valid estimates of the components of variation can be obtained from relatively small numbers of specimens collected from a small group of subjects over a reasonably short period of time. 8 We based on this theory to design and implement the study of biological variation. Data regarding biological variation should be accompanied by name of manufacturer and methodology since methods change with time. 15 Biological variation is an inherent variation that should be determined excluding preanalytical and analytical variation. In this study, we used standardized sample collection, processing, and analysis protocols to minimize pre-analytical and analytical variation.
All analytical tests were conducted by the same technician using the same reagents. The analytical variations in our study were small (all <5%). This result achieved the general goal that analytical variation should be less than half of the intra-individual variation, and confirmed the accuracy of our data.
The intra-and inter-biological variations for NSE were 10.1% and 12.0%, respectively. These results were consistent with those reported previously by Braga et al 11 and Qi et al 12 Long-term and short-term biological variations were similar. We found only one published study 12 on the biological variation of CA724, which reported that the intra-individual biological variation was 16.1%, whereas the inter-individual biological variation was 97.0%. In our study, the intra-individual biological variation of CA724 was much larger than that in the previous report, 50.3%, whereas the interindividual biological variation (103.4%) was similar with that in the previous report. The difference was due primarily to different sampling intervals. We collected samples every week for 5 weeks, whereas Qi et al 12 collected samples daily only for 5 days. We chose Reference intervals are insensitive for CA724, especially for determining whether a change was clinically significant. The overall II for NSE in our study was 0.85, which is higher than 0.6 but still less than 1.4.
When we evaluate the result of serum NSE, both the reference interval and biological variation should be considered. Tumor markers are typically used for monitoring disease and not for cancer diagnosis.
Therefore, serum CA724 and NSE with a low index are ideal for this purpose.
| CONCLUSION
We used standardized methods to estimate weekly biological variations of serum NSE and CA724 for 5 weeks in 20 healthy subjects. We also calculated RCV and II. Our results showed that II was low for both NSE and CA724, which suggests that we should pay attention to the RCV when assessing patient results.
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